Monoclonal antibody · Antagonist of insulin receptor (INSR)
Ersodetug is a fully human IgG2 monoclonal antibody that binds the insulin receptor (INSR) and allosterically reduces INSR-mediated signaling by insulin and related hormones such as IGF-2. It is being studied in tumor hyperinsulinism and congenital hyperinsulinism, conditions causing hypoglycemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06881992 | Phase 3 | Tumor Hyperinsulinism (Tumor HI) | Recruiting | RZLT |
| NCT06208215 | Phase 3 | Congenital Hyperinsulinism | Active not recruiting | RZLT |
| NCT04538989 | Phase 2 | Congenital Hyperinsulinism | Completed | RZLT |
| NCT07262970 | N/A | Tumor-associated Hyperinsulinism (Tumor HI) | Available | RZLT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Tumor Hyperinsulinism (Tumor HI)Congenital HyperinsulinismTumor-associated Hyperinsulinism (Tumor HI)
Updated Nov 1, 2026.